Redmile Group, LLC Akero Therapeutics, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q3 2024

A detailed history of Redmile Group, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 1,387,479 shares of AKRO stock, worth $36.2 Million. This represents 2.6% of its overall portfolio holdings.

Number of Shares

1,387,479

Previous 1,614,473 14.06%

Holding current value

$36.2 Million

Previous $37.9 Million 5.1%

% of portfolio

2.6%

Previous 2.47%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $4.87 Million - $6.66 Million	-226,994 Reduced 14.06%	1,387,479 $39.8 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $4.47 Million - $6.01 Million	-244,229 Reduced 13.14%	1,614,473 $37.9 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $13.3 Million - $23.4 Million	749,226 Added 67.53%	1,858,702 $47 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $7.99 Million - $35.3 Million	-702,196 Reduced 38.76%	1,109,476 $25.9 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $8.58 Million - $13.2 Million	-232,717 Reduced 11.38%	1,811,672 $84.6 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $21.9 Million - $29.6 Million	-588,523 Reduced 22.35%	2,044,389 $78.2 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $34.8 Million - $57.1 Million	1,041,827 Added 65.48%	2,632,912 $144 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $38,570 - $129,389	3,800 Added 0.24%	1,591,085 $54.2 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $120,000 - $225,150	-15,000 Reduced 0.94%	1,587,285 $15 Million
Q4 2021 Feb 14, 2022	SELL	$19.87 - $26.24 $21.6 Million - $28.5 Million	-1,085,159 Reduced 40.38%	1,602,285 $33.9 Million
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $2.19 Million - $2.99 Million	-117,500 Reduced 4.19%	2,687,444 $60.1 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $7.22 Million - $9.42 Million	291,198 Added 11.58%	2,804,944 $69.6 Million
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $4.6 Million - $6.54 Million	191,189 Added 8.23%	2,513,746 $72.9 Million
Q4 2020 Feb 16, 2021	SELL	$25.12 - $29.89 $346,656 - $412,482	-13,800 Reduced 0.59%	2,322,557 $59.9 Million
Q3 2020 Nov 16, 2020	BUY	$30.79 - $39.92 $59.9 Million - $77.6 Million	1,944,205 Added 495.78%	2,336,357 $71.9 Million
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $3.41 Million - $4.75 Million	-177,361 Reduced 31.14%	392,152 $9.77 Million
Q1 2020 May 15, 2020	SELL	$12.8 - $27.05 $7.61 Million - $16.1 Million	-594,489 Reduced 51.07%	569,513 $12.1 Million
Q4 2019 Feb 14, 2020	SELL	$17.37 - $27.27 $6,948 - $10,908	-400 Reduced 0.03%	1,164,002 $25.8 Million
Q3 2019 Nov 14, 2019	SELL	$16.89 - $29.88 $74,316 - $131,472	-4,400 Reduced 0.38%	1,164,402 $26.5 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $21.1 Million - $23.2 Million	1,168,802 New	1,168,802 $22.4 Million

Others Institutions Holding AKRO

# of Institutions

191

Shares Held

74.6M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.21B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Akero Therapeutics, Inc. Transaction History